Lung Cancer

March 04, 2021

The FDA expanded the indication for lorlatinib to include the front-line treatment of patients with ALK-positive non–small cell lung cancer.

February 24, 2021

The FDA has approved the PD-L1 IHC 22C3 pharmDx assay, developed by Agilent Technologies Inc, for expanded use in patients with non–small cell lung cancer.

February 23, 2021

Immunotherapy continues to improve upon the treatment of non-small cell lung cancer, and there are more exciting advancements on the horizon.

February 22, 2021

The FDA approved single-agent frontline cemiplimab-rwlc (Libtayo) for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a PD-L1 expression of 50% or greater.

February 17, 2021

The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy.

February 12, 2021

The FDA has approved trilaciclib to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer.

February 08, 2021

“We should never be complacent; we should never be skeptical,” said Lilenbaum. “We need to continue to pursue new treatments, and if nothing else, the past 2 decades are a testament to how we can actually make a difference in the natural history of the disease by appropriate interventions.”

February 07, 2021

Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.

February 06, 2021

Health-related quality of life (HRQoL) was maintained for patients with EGFR-positive non–small cell lung cancer (NSCLC) who received treatment with adjuvant osimertinib (Tagrisso) versus placebo, with no clinically meaningful differences noted between study arms, according to an analysis on patient-reported outcomes (PROs) from the phase 3 ADAURA trial.

February 03, 2021

The FDA approved tepotinib (Tepmetko) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with MET exon 14-skipping alterations, according to the FDA.